drugset
drugset / Trial / NCT03932006

A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis

NCT03932006 ↗

Phase 4 Unknown 180 enrolled Sun Yat-sen University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Fengshigutong Capsule in the treatment of active ankylosing spondylitis(AS). The primary purpose is to assess the different maintaining treatment programme in AS patients with controlled inflammation by Imrecoxib. The trial will include 180 patients who will be divided into three group: Fengshigutong Capsule plus Imrecoxib group, Imrecoxib group and Fengshigutong Capsule group. Patients will complete the 4-week therapy.

Timeline

Start
2016-06-30
Primary completion
2019-05-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fengshigutong Capsule Unknown 1.2 g Oral
Comparator Imrecoxib Small molecule 0.1 g Oral

Indications

ankylosing spondylitis